Your fact-checks will appear here
CLARITY-AD trial results, including infusion reaction rates for lecanemab
Infusion centers that plan to deliver must expand beyond routine infusion capacity: they need protocols and physical space for repeated IV infusions, rapid access to MRI and laboratory testing for sur...
Anti‑amyloid monoclonal antibodies differ in what forms of Aβ they bind, how much they lower brain amyloid and downstream biomarkers, and in clinical benefit versus risk balance: lecanemab targets sol...
The randomized trials of lecanemab and donanemab showed statistically significant slowing of cognitive and functional decline over 18 months, but the absolute differences were small versus placebo and...